OncoSec Medical (NASDAQ:ONCS) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday, ValuEngine reports.
A number of other analysts have also commented on ONCS. Zacks Investment Research lowered OncoSec Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, July 24th. Maxim Group reaffirmed a “buy” rating and issued a $10.00 target price on shares of OncoSec Medical in a research report on Friday, June 28th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $19.75.
OncoSec Medical stock traded down $0.06 during midday trading on Thursday, reaching $2.11. The stock had a trading volume of 139,297 shares, compared to its average volume of 141,623. OncoSec Medical has a 12 month low of $2.02 and a 12 month high of $19.60. The business has a fifty day moving average price of $2.44.
In other news, Director Alpha Holdings, Inc. bought 491,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was acquired at an average cost of $3.14 per share, with a total value of $1,541,740.00. Following the transaction, the director now directly owns 10,491,000 shares of the company’s stock, valued at approximately $32,941,740. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 5.40% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its stake in OncoSec Medical by 98.2% during the 4th quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock valued at $311,000 after purchasing an additional 240,843 shares during the last quarter. Geode Capital Management LLC boosted its stake in OncoSec Medical by 72.5% during the 4th quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 163,405 shares during the last quarter. Northern Trust Corp boosted its stake in OncoSec Medical by 33.6% during the 4th quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 28,914 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in OncoSec Medical by 484.1% during the 4th quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 83,150 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.
OncoSec Medical Company Profile
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
Read More: What is quantitative easing?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.